- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
March 13th, 2008
START chosen to test drug compound that suppresses cancer-causing genes
South Texas Accelerated Research Therapeutics (START) has been selected as one of two clinics that will conduct Phase I trials for an anti-cancer compound developed by Calando Pharmaceuticals.
Calando also submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration to initiate the clinical trial for the drug, CALAA-01.
The drug is a targeted nanoparticle designed to activate the body's natural mechanism to "silence" the "inappropriate activity" of specific genes causing cancer. The trial will evaluate whether CALAA-01 is safe and tolerable by humans. Anthony Tolcher, M.D., director of clinical research at START, will be leading the study in San Antonio.
START is a partnership that directs clinical trials of novel anticancer agents and is headquartered at San Antonio's South Texas Medical Center. The group is constructing a new 120,000-square-foot office headquarters building, scheduled to open in July 2008.
|Related News Press|
News and information
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016